- Home
- AMAL vs NUVB Comparison
AMAL vs NUVB Comparison
Compare AMAL & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- NUVB
- Stock Information
- Founded
- AMAL 1923
- NUVB 2018
- Country
- AMAL United States
- NUVB United States
- Employees
- AMAL N/A
- NUVB N/A
- Industry
- AMAL Commercial Banks
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- NUVB Health Care
- Exchange
- AMAL Nasdaq
- NUVB Nasdaq
- Market Cap
- AMAL 1.0B
- NUVB 959.2M
- IPO Year
- AMAL 2018
- NUVB N/A
- Fundamental
- Price
- AMAL $36.10
- NUVB $2.51
- Analyst Decision
- AMAL Buy
- NUVB Strong Buy
- Analyst Count
- AMAL 4
- NUVB 6
- Target Price
- AMAL $37.13
- NUVB $7.00
- AVG Volume (30 Days)
- AMAL 153.9K
- NUVB 3.0M
- Earning Date
- AMAL 01-23-2025
- NUVB 02-27-2025
- Dividend Yield
- AMAL 1.33%
- NUVB N/A
- EPS Growth
- AMAL 16.43
- NUVB N/A
- EPS
- AMAL 3.39
- NUVB N/A
- Revenue
- AMAL $303,032,000.00
- NUVB $2,162,000.00
- Revenue This Year
- AMAL N/A
- NUVB N/A
- Revenue Next Year
- AMAL $4.24
- NUVB $369.72
- P/E Ratio
- AMAL $10.65
- NUVB N/A
- Revenue Growth
- AMAL 12.76
- NUVB N/A
- 52 Week Low
- AMAL $21.33
- NUVB $1.44
- 52 Week High
- AMAL $38.19
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- AMAL 64.23
- NUVB 42.25
- Support Level
- AMAL $31.87
- NUVB $2.44
- Resistance Level
- AMAL $35.59
- NUVB $2.77
- Average True Range (ATR)
- AMAL 0.84
- NUVB 0.23
- MACD
- AMAL 0.33
- NUVB -0.04
- Stochastic Oscillator
- AMAL 100.00
- NUVB 6.40
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers a range of products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).